期刊文献+

盐酸替罗非班氯化钠注射液联合心血管介入治疗急性心肌梗死患者的临床效果与安全性探讨 被引量:12

下载PDF
导出
摘要 目的:探讨急性心肌梗死患者应用盐酸替罗非班氯化钠注射液联合心血管介入治疗的临床效果.方法:将我院2014-01/2015-06收治的符合诊断标准的60例急性心肌梗死患者随机分为对照组(n=30)和实验组(n=30).对照组实施常规血管介入治疗,实验组联合盐酸替罗非班氯化钠注射液以及心血管介入治疗.观察和比较两组患者的治疗情况以及预后.结果:两组患者的TMPG灌注经比较,实验组的TMPG灌注3级比率为66.7%,高于对照组的43.3%,差异有统计学意义(P<0.05).两组患者的血小板活化功能改善情况比较,实验组优于对照组,差异有统计学意义(P<0.05);两组患者并发症发生率比较差异无统计学意义(P>0.05);实验组的不良心脏事件发生率低于对照组,差异有统计学意义(P<0.05).结论:应用盐酸替罗非班氯化钠联合心血管介入治疗急性心肌梗死患者,安全性高,治疗效果确切,值得临床推广.
作者 张同强
出处 《转化医学电子杂志》 2015年第9期44-45,共2页 E-Journal of Translational Medicine
  • 相关文献

二级参考文献56

  • 1陈跃峰,杨跃进.经皮冠状动脉介入治疗术后的无再流现象[J].心血管病学进展,2005,26(1):4-8. 被引量:48
  • 2GIBSON C M, CANNON C P, MUPHY S A, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs [J] Circulation, 2000,101 : 125 - 130.
  • 3BROSH D, ASSALI A R, MAGER A, et al. Effect of no-flow during primary percutaneous coronary in tervention for acute myocardial infarction on six- month mortality[J]. Am J Cardiol, 2007, 99:442 - 445.
  • 4MOVAHED M R, BUTMAN S M. The pathogenesis and treatment of no-flow occurring during percutaneous coronary intervention [J]. Cardiovasc Revase Med,2008,9:56-61.
  • 5OLDENBURG O, EGGEBRECHT H, HERRMANN J, et al. Dose dependent effects of intracoronary verapamil on systemic and coronary hemodynamics[J]. Cardiovasc Drugs Ther, 2000,14 : 651 - 655.
  • 6WERNER G S, LANG K, KUEHNERT H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infaretion[J]. Catheter Cardiovasc Interv, 2002 , 57 : 444 - 451.
  • 7UMI~MURA S, NAKAMURA S, SUGIARA T, et al. The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographie no-reflow after primary pereutaneous coronary intervention [J]. Nucl Med Commun, 2006,27:247-254.
  • 8NICCOI.I G,MARZO F, PAGLIA A, et al. Preprocedural N-terminal pro-B-type natriuretic peptide predicts angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction[J]. Circulation, 2007,116:Ⅱ - 630.
  • 9VAN'T HOF A W, VALGIMIGLI M. Defining the role of platelet glycopretein recertor inhibitors in STEMI : focus on tirfiban[J]. Drugs, 2009,69: 85 - 100.
  • 10VAN'T HOF A W, TEN BERG J, HEESTERMANS T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty ( On-TIMI2 ) : a multicentre, double-blind, randomised contyolled trial[J]. Lancet, 2008,16:537-546.

共引文献123

同被引文献78

引证文献12

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部